Daniel T Baptista-Hon

Dr. Daniel T Baptista-Hon

Macau University of Science and Technology, Macao, China
+1
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2021 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
SSSamuel Singleton
Samuel Singleton
DBDaniel T Baptista-Hon
Daniel T Baptista-Hon
EEEmily Edelsten
Emily Edelsten
KMKirsty S. McCaughey
Kirsty S. McCaughey
ECEwan Camplisson
Ewan Camplisson
THTim G. Hales
Tim G. Hales
Background and Purpose: β‐Arrestin2 recruitment to μ‐receptors may contribute to the development of opioid side effects. This possibility led to the development of TRV130 and PZM21, opioids reportedly biased against β‐arrestin2 recruitment in favour of G‐protein signalling. However, low efficacy β‐arrestin2 recruitment by TRV130 and PZM21 may simply reflect partial agonism overlooked due to overexpression of μ‐receptors.Experimental Approach: Efficacies and apparent potencies of DAMGO, morphine, PZM21 and TRV130 as stimulators of β‐arrestin2 recruitment and inhibitors of cAMP accumulation were assessed in CHO cells stably expressing μ‐receptors. Receptor availability was depleted through prior exposure of cells to the irreversible antagonist, β‐FNA. We also examined whether μ‐receptor availability influences TRV130 anti‐nociception and/or tolerance using the tail withdrawal assay in wild‐type C57BL/6 and μ+/− mice.Key Results: Morphine, PZM21 and TRV130 were partial agonists in the β‐arrestin2 recruitment assay. Only TRV130 exhibited partial agonism in the cAMP assay. Exposure to β‐FNA to reduce μ‐receptor availability further limited the efficacy of TRV130 and revealed morphine and PZM21 to be partial agonists. Despite having partial efficacy in vitro, TRV130 caused potent anti‐nociception (ED50: 0.33 mg·kg−1) in wild‐type mice, without tolerance after daily administration for 10 days. TRV130 caused similar anti‐nociception in μ+/− mice, with marked tolerance on day 4 of injections.Conclusion and Implications: Our findings emphasise the importance of receptor reserve when characterising μ‐receptor agonists. Reduced receptor availability reveals that TRV130 is a partial agonist capable of tolerance, despite having limited efficacy for β‐arrestin2 recruitment to the μ‐receptor.

16 February 2026 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
ZLZhenghao Li
Zhenghao Li
WDWende Deng
Wende Deng
LYLanxuan Yang
Lanxuan Yang
CTChangheng Tang
Changheng Tang
JYJian-Min Yue
Jian-Min Yue
TLTing Li
Ting Li
Lipid metabolism is essential for maintaining cellular homeostasis, and its dysregulation is linked to various diseases, including cancer, cardiovascular disease, and diabetes. Immune cells, such as macrophages, T cells, B cells, and neutrophils, rely on lipid metabolism for their function, which impacts both innate and adaptive immune responses. Understanding how lipid metabolism influences immune cells is crucial, as it can reveal new therapeutic opportunities for immune-mediated diseases. In this review, we provide a retrospective summary of the research history and milestone events in lipid metabolism research and highlight the importance of lipid metabolism in immune cells. In addition to discussing the various lipid functions, transport, and signaling pathways involved in lipid metabolism, we mainly explore the regulation of immune cell behavior by lipid metabolism, focusing on the roles of lipid metabolites in immune cell proliferation, differentiation, and activation. We further highlight multilevel regulatory mechanisms, including genetic, epigenetic, posttranscriptional, and posttranslational regulation, and their impact on immune cell function. Additionally, we discuss the role of lipid metabolism in diseases such as autoimmune diseases, cancer, neurodegenerative diseases, cardiovascular diseases, aging, and metabolic disorders. Finally, we summarize therapeutic strategies targeting lipid metabolism, the progress of global clinical trials, and future research directions, including lipid-derived biomarkers and innovative therapeutic approaches.

16 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ULUt Sam Lao
Ut Sam Lao
CLChak Fun LAW
Chak Fun LAW
DBDaniel T Baptista-Hon
Daniel T Baptista-Hon
Brian TomlinsonBrian Tomlinson
Brian Tomlinson
There is mounting evidence that statin use is beneficial for COVID-19 outcomes. We performed a systematic review and meta-analysis to evaluate the association between statin use and mortality, intensive care unit (ICU) admission and mechanical ventilation in COVID-19 patients, on studies which provided covariate adjusted effect estimates, or performed propensity score matching. We searched PubMed, Embase, Web of Science and Scopus for studies and extracted odds or hazard ratios for specified outcome measures. Data synthesis was performed using a random-effects inverse variance method. Risk of bias, heterogeneity and publication bias were analyzed using standard methods. Our results show that statin use was associated with significant reductions in mortality (OR = 0.72, 95% CI: 0.67–0.77; HR = 0.74, 95% CI: 0.69, 0.79), ICU admission (OR = 0.94, 95% CI: 0.89–0.99; HR = 0.76, 95% CI: 0.60–0.96) and mechanical ventilation (OR = 0.84, 95% CI: 0.78–0.92; HR = 0.67, 95% CI: 0.47–0.97). Nevertheless, current retrospective studies are based on the antecedent use of statins prior to infection and/or continued use of statin after hospital admission. The results may not apply to the de novo commencement of statin treatment after developing COVID-19 infection. Prospective studies are lacking and necessary.

6 February 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
CKChien-Wen S. Kuo
Chien-Wen S. Kuo
SDSara Dobi
Sara Dobi
CGCaglar Gök
Caglar Gök
ACAna Da Silva Costa
Ana Da Silva Costa
AMAlice Main
Alice Main
WFWilliam Fuller
William Fuller
Mammalian voltage-activated L-type Ca 2+ channels, such as Ca(v)1.2, control transmembrane Ca 2+ fluxes in numerous excitable tissues. Here, we report that the pore-forming α1C subunit of Ca(v)1.2 is reversibly palmitoylated in rat, rabbit, and human ventricular myocytes. We map the palmitoylation sites to two regions of the channel: The N terminus and the linker between domains I and II. Whole-cell voltage clamping revealed a rightward shift of the Ca(v)1.2 current–voltage relationship when α1C was not palmitoylated. To examine function, we expressed dihydropyridine-resistant α1C in human induced pluripotent stem cell-derived cardiomyocytes and measured Ca 2+ transients in the presence of nifedipine to block the endogenous channels. The transients generated by unpalmitoylatable channels displayed a similar activation time course but significantly reduced amplitude compared to those generated by wild-type channels. We thus conclude that palmitoylation controls the voltage sensitivity of Ca(v)1.2. Given that the identified Ca(v)1.2 palmitoylation sites are also conserved in most Ca(v)1 isoforms, we propose that palmitoylation of the pore-forming α1C subunit provides a means to regulate the voltage sensitivity of voltage-activated Ca 2+ channels in excitable cells.

2 April 2025 in MedComm – Future Medicine
Verified
Journal Article
Open access
NPNivritti Gajanan Patil
Nivritti Gajanan Patil
NKNga Lok Kou
Nga Lok Kou
DBDaniel T Baptista-Hon
Daniel T Baptista-Hon
OMOlivia Monteiro
Olivia Monteiro
Artificial intelligence (AI)‐driven learning is transforming education, requiring educators to quickly develop the skills to integrate AI tools effectively so they complement rather than replace traditional teaching practices. The fast pace of generative AI development poses challenges, particularly for less tech‐savvy teachers or those who delay learning about these tools, leaving them at risk of falling behind. This is further compounded by students' quick adaptation to widely available models such as ChatGPT‐3.5 and Deepseek R1, which they increasingly use for learning, assignments, and assessments. Despite existing discussions on AI in education, there is a lack of practical guidance on how medical educators can effectively and responsibly implement AI tools in teaching. This perspective provides a practical guide for medical educators to effectively incorporate AI tools to complement their teaching strategies, generate student assessments and to adapt assignments suitable for the AI era. We address challenges such as data bias, accuracy, and ethics, ensuring AI enhances rather than undermines medical training when aligned with sound pedagogical principles. This review provides a practical, structured approach for educators, offering clear recommendations to help bridge the gap between AI advancements and effective teaching methodologies in medical education.

4 April 2020 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
DBDaniel T Baptista-Hon
Daniel T Baptista-Hon
MSMark Smith
Mark Smith
SSSamuel Singleton
Samuel Singleton
LALysbeth H. Antonides
Lysbeth H. Antonides
NDNiamh Nic Daeid
Niamh Nic Daeid
THTim G. Hales
Tim G. Hales
Background and Purpose: A fluorinated derivative (2F‐MT‐45) of the synthetic μ‐opioid receptor agonist MT‐45 (1‐cyclohexyl‐4‐(1,2‐diphenylethyl)piperazine) was recently identified in a seized illicit tablet. While MT‐45 is a Class A drug, banned in a number of countries, nothing is known about the pharmacology of 2F‐MT‐45. This study compares the pharmacology of MT‐45, its fluorinated derivatives and two of its metabolites.Experimental Approach: We used a β‐arrestin2 recruitment assay in CHO cells stably expressing μ receptors to quantify the apparent potencies and efficacies of known (MT‐45, morphine, fentanyl and DAMGO) and potential agonists. In addition, the GloSensor protein was transiently expressed to quantify changes in cAMP levels. We measured Ca2+ to investigate whether MT‐45 and its metabolites have effects on GluN1/N2A NMDA receptors stably expressed in Ltk‐ cells.Key Results: The fluorinated MT‐45 derivatives have higher apparent potencies (2F‐MT‐45: 42 nM) than MT‐45 (1.3 μM) for inhibition of cAMP accumulation and β‐arrestin2 recruitment (2F‐MT‐45: 196 nM; MT‐45: 23.1 μM). While MT‐45 and 2F‐MT‐45 are poor recruiters of β‐arrestin2, they have similar efficacies for reducing cAMP levels as DAMGO. Two MT‐45 metabolites displayed negligible potencies as μ receptor agonists, but one, 1,2‐diphenylethylpiperazine, inhibited the NMDA receptor with an IC50 of 29 μM.Conclusion and Implications: Fluorinated derivatives of MT‐45 are potent μ receptor agonists and this may pose a danger to illicit opioid users. Inhibition of NMDA receptors by a metabolite of MT‐45 may contribute to the reported dissociative effects.